GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Cash Flow from Operations

Algorae Pharmaceuticals (ASX:1AI) Cash Flow from Operations : A$-1.84 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2023, Algorae Pharmaceuticals's Cash Receipts from Operating Activities was A$0.00 Mil. Its Cash Payments was A$-1.04 Mil. Its Dividends Paid was A$0.00 Mil. Its Dividends Received was A$0.00 Mil. Its Interest Paid was A$0.00 Mil. Its Interest Received was A$0.03 Mil. Its Taxes Refund Paid was A$0.00 Mil. And its Cash Flow from Others was A$0.00 Mil. In all, Algorae Pharmaceuticals's Cash Flow from Operations for the six months ended in Dec. 2023 was A$-1.01 Mil.


Algorae Pharmaceuticals Cash Flow from Operations Historical Data

The historical data trend for Algorae Pharmaceuticals's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Cash Flow from Operations Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.99 -3.11 -1.46 -2.04 -1.99

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 -1.45 -1.15 -0.83 -1.01

Algorae Pharmaceuticals Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Algorae Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Jun. 2023 is calculated as:

Algorae Pharmaceuticals's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (ASX:1AI) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Algorae Pharmaceuticals's cash receipts from operating activities for the six months ended in Dec. 2023 was A$0.00 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Algorae Pharmaceuticals's cash payments for the six months ended in Dec. 2023 was A$-1.04 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Algorae Pharmaceuticals's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Algorae Pharmaceuticals's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Algorae Pharmaceuticals's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Algorae Pharmaceuticals's cash payments for the six months ended in Dec. 2023 was A$0.03 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Algorae Pharmaceuticals's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Algorae Pharmaceuticals's cash flow from others for the six months ended in Dec. 2023 was A$0.00 Mil.


Algorae Pharmaceuticals Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (ASX:1AI) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines